INVEGA TRINZA® Common Dosing and Administration Topics

Switching

From Long-acting Injectable (LAI) Antipsychotics

Consistent with the INVEGA TRINZA® Prescribing Information:

  • INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months. In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.
  • Patients entering the open-label phase of a long-term double-blind, placebo-controlled randomized-withdrawal trial who were being treated with 25 mg, 37.5 mg, or 50 mg of risperidone long-acting injection were switched to 78 mg, 117 mg, or 156 mg, respectively, of INVEGA SUSTENNA® administered in the deltoid muscle.
  • Patients entering the study who were being treated with any other LAI product were switched to 234 mg of INVEGA SUSTENNA® administered in the deltoid muscle.

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:

INVEGA SUSTENNA® for:

  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants

INVEGA TRINZA® for:

  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm

×

Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel